July 2008

Academic research is fueling tremendous strides in oncology and biotechnology. The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

New research presented at ASCO highlights advantages of pegfilgrastim in patients receiving chemotherapy for a wide variety of solid tumors and hematologic malignancies.

Oral mucositis is a costly consequence of cancer therapy that can impede the efficacy of anticancer therapy. Simple preventive measures can greatly improve the patient�s outcome and quality of life.

Researchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.

The American Society of Clinical Oncology (ASCO) held its 44th Annual Clinical Meeting in Chicago. Leading oncologists and cancer researchers at centers from around the world presented new basic and clinical research findings to advance the care of cancer.

This issue of Oncology & Biotech News presents significant sessions and posters from the 44th annual meeting of the American Society of Clinical Oncology (ASCO) plus stories on drive-through breast cancer surgery centers, cancer patients' out-of-pocket costs, and more.